|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Silicon carbide resonant tuning fork for microsensing applications in high-temperature and high G-shock environments显示文摘We present the fabrication and testing of a silicon carbide(SiC)balanced mass double-ended tuning fork that survives harsh environments without compromising the device strain sensitivity and resolution bandwidth.The device features a material stack that survives corrosive environments and enables high-temperature operation.To perform high-temperature testing,a specialized setup was constructed that allows the tuning fork to be characterized using traditional silicon electronics.The tuning fork has been operated at 600 ℃ in the presence of dry steam for short durations.This tuning fork has also been tested to 64 000 G using a hard-launch,soft-catch shock implemented with a light gas gun.However,the device still has a strain sensitivity of 66 Hz/με and strain resolution of 0.045 με in a 10 kHz bandwidth.As such,this balanced-mass double-ended tuning fork can be used to create a variety of different sensors including strain gauges,accelerometers,gyroscopes,and pressure transducers.Given the adaptable fabrication process flow,this device could be useful to micro-electro-mechanical systems(MEMS) designers creating sensors for a variety of different applications. | David R Myers Kan Bun Cheng Babak Jamshidi Robert G Azevedo Debbie G Senesky Li Chen Mehran Mehregany Muthu B J Wijesundara Albert P Pisano | 2012 | Engineering Sciences2012，10，5： | 6 |
| 2 | Predictive biomarkers in precision medicine and drug development against lung cancer显示文摘The molecular characterization of various cancers has shown that cancers with the same origins,histopathologic diagnoses,and clinical stages can be highly heterogeneous in their genetic and epigenetic alterations that cause tumorigenesis.A number of cancer driver genes with functional abnormalities that trigger malignant transformation and that are required for the survival of cancer cells have been identified.Therapeutic agents targeting some of these cancer drivers have been successfully developed,resulting in substantial improvements in clinical symptom amelioration and outcomes in a subset of cancer patients.However,because such therapeutic drugs often benefit only a limited number of patients,the successes of clinical development and applications rely on the ability to identify those patients who are sensitive to the targeted therapies.Thus,biomarkers that can predict treatment responses are critical for the success of precision therapy for cancer patients and of anticancer drug development.This review discusses the molecular heterogeneity of lung cancer pathogenesis;predictive biomarkers for precision medicine in lung cancer therapy with drugs targeting epidermal growth factor receptor(EGFR),anaplastic lymphoma kinase(ALK),c-ros oncogene 1 receptor tyrosine kinase[ROSl),and immune checkpoints;biomarkers associated with resistance to these therapeutics;and approaches to identify predictive biomarkers in anticancer drug development.The identification of predictive biomarkers during anticancer drug development is expected to greatly facilitate such development because it will increase the chance of success or reduce the attrition rate.Additionally,such identification will accelerate the drug approval process by providing effective patient stratification strategies in clinical trials to reduce the sample size required to demonstrate clinical benefits. | Bingliang Fang Reza J Mehran John V Heymach Stephen G Swisher | 2015 | Chinese Journal of Cancer2015，34，7： | 5 |
| 3 | Combination therapy with aspirin plus clop idogrel versus aspirin plus ticlopidine for p revention of subacute thrombosis after successful native coronary stenting显示文摘 | Dangas G Mehran R Abizaid AS | 2001 | Am J Cardiol2001，87，4： | 1 |
| 4 | Acute renal failure requiring dialysis after percutaneous coronary interventions显示文摘 | Gruberg L Mehran R Dangas G | 2001 | Cathet Cardiovasc Interven2001，52，4： | 1 |
| 5 | Hyper- insulinemia drives diet- induced obesity independently of brain insulin production 显示文摘 | Mehran A E Templeman N M Beigidi G S | 2012 | Cell Metabolism2012，16，6： | 1 |
| 6 | Stable coronary artery disease: revascularisation and invasive strategies 显示文摘 | Piccolo R Giustino G Mehran R | 2015 | Lancet2015，386，： | 1 |
| 7 | Angiogaphic patterns of in-stent restenosis:classification and implication for long-term outcomes 显示文摘 | Mehran R Dangas G Abizaid AS | 1999 | Circulation1999，100，： | 1 |
| 8 | Angiographic patterns of in-stent restenosis:classfication and implications for long-term outcome显示文摘 | Mehran R Dangas G Abizaid AS | 1999 | Circulation1999，100，： | 1 |
| 9 | Lipiprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation 显示文摘 | DANGAS G MEHRAN R HARPEL PC | 1998 | Am Coll Cardiol1998，32，7： | 1 |
| 10 | Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty:results from the HORIZONS-AMI (harmonizing outcomes with revescularization and stents in acute myocardial infarction) trial显示文摘 | Dangas G Mehran R Guagliumi G | 2009 | J Am Coll Cardiol2009，54，15： | 1 |
| 11 | Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: Results from the INFUSE‐AMI study显示文摘 | Elias A. Sanidas Sorin J. Brener Akiko Maehara Philippe Généreux Bernhard Witzenbichler Magdi El‐Omar Martin Fahy Roxana Mehran C. Michael Gibson Gregg W. Stone | 2014 | Cathet Cardiovasc Intervent2014，，5： | 1 |
| 12 | Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis显示文摘 | Mehran R Mintz G S Popma J J | 1996 | Am J Cardiol1996，78，： | 1 |
| 13 | Risk factors for the development of slow flow during rotational coronary atherectomy显示文摘 | Sharma S K Dangas G Mehran R | 1997 | Am J Cardiol1997，80，： | 1 |
| 14 | Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices显示文摘 | Dangas G Mehran R Kokolis S | 2001 | J Am Coll Cardiol2001，38，： | 1 |
| 15 | Clinical outcome fol-lowing percutaneous coronary interventions in patients with chronic renal failure 显示文摘 | Gruberg L Dangas G Mehran R | 2002 | Catheter Cardiovasc Interv2002，55，1： | 1 |
| 16 | Lipoprotein (α) and inflammation in human coronary atheroma: association with the severity of clinical presentation 显示文摘 | Dangas G Mehran R Harpel PC | 1998 | J Am Coll Cardiol1998，32，7： | 1 |
| 17 | Long-term fol- low- up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings:importance of lumen dimensions 显示文摘 | ABIZAID A S MINTZ G S MEHRAN R | 1999 | Circulation1999，100，3： | 1 |
| 18 | Comparison of differences in outcome after percutaneous coronary intervention in men versus women <40 years of age显示文摘 | Lansky AJ Mehran R Dangas G | 2004 | Am J Cardiol2004，，93： | 1 |
| 19 | Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty显示文摘 | DANGAS G MEHRAN R GUAGLIUMI G | 2009 | J Am Coll Cardiol2009，54，10： | 1 |
| 20 | Restenosis After Coronary Angioplasty显示文摘 | Hong M Mehran R Mintz G | 1997 | Curr Probl cardiol1997，22，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员